In T2DM with CKD, semaglutide reduced major kidney disease events at 3 y.
Where this comes from
- Record sourced from PubMed, PMID 39222509.
- Also identified by DOI 10.7326/ANNALS-24-01579-JC.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Perkovic V, Tuttle KR, Rossing P, et al; FLOW Trial Committees and Investigators. <b>Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes.</b> N Engl J Med. 2024;391:109-121. 38785209.